Session: SAT 109-133-GHRH, GH & IGF Biology & Signaling
Bench to Bedside
Poster Board SAT-118
Soluble Klotho (sKl) levels are markedly elevated in patients with acromegaly and decline with successful surgical therapy suggesting a causal relationship between GH-excess and sKl. It is unknown, whether (i) GH-deficient patients (GHD) have lower sKl levels than control subjects and (ii) GH replacement therapy (GHRT) results in an increase in sKl concentrations. We, therefore, measured sKI levels in GH-deficient patients before and after GHRT and in sedentary healthy controls (CS) matched for gender, age, BMI and waist.
Ten patients with GHD (4 female and 6 male patients; age:42±12.5, mean±SD, years; BMI: 26.6±3.8, kg/m2; waist:89.3±12.9, cm) and ten healthy controls (age: 42.8±12.6; BMI: 25.2±5.3; waist:90.7±19.1) were included in this study. Identical investigations (anthrompometric and biochemical evaluation) were performed in the GHD (before and after 6 months GHRT) and in the CS. Serum sKl was measured by an ELISA, IGF-1 concentrations by Immunolite (SIEMENS).
Anthropometric data were not significatly different between GHD and CS. GHRT did not result in a significant change in BMI or waist. GHD exhibited a reduced IGF- concentration compared to CS (GHD: median (IQR): 68.5 ng/mL (46.9–68.2) vs CS: 111.5 (98.8 – 130.3); p<0.005). sKI concentrations were not significantly different between GHD and CS. GHRT resulted in a significant increase in IGF-1 levels (GHD: 68.5 ng/mL (46.9-68.2) vs GHRT: 153.0 (117.3-149.5; p<0.002) and sKI concentrations (GHD:497 pg/mL (419-658) vs GHRT 692 (590-1233); p=0.002)
These findings (i) confirm a causal relationship between GH and sKl but (ii) show that sKl is not particularly low in GHD (not significantly different from CS).
Nothing to Disclose: RL, AE, CZ, LS, CS, ERC
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters